Heng Score for Metastatic Renal Cell Carcinoma (RCC) Prognosis
Patients with mRCC treated with modern VEGF therapy.
This score placed subjects with metastatic renal cell carcinoma (mRCC) treated with modern VEGF therapies (e.g. sunitinib) into three survival groups: poor, intermediate, and favorable. Both the derivation and validation are chart review studies; however, both found similar results. Prospective validation is eagerly awaited.
There are no validated scoring systems for predicting survival in mRCC. Using a score may help sketch categories of survival time better than clinical judgment alone.
Please fill out required fields.
The Heng score (Database Consortium Model) has theoretical advantages over some other scores:
- A successful validation study.
- Focus on those receiving modern treatments in common practice.
While the score has not been shown to be accurate in any prospective study it may be among the most likely to correctly predict survival categories.
We are unaware of validated management algorithms using the score.
The Heng score is relevant exclusively to mRCC patients undergoing VEGF therapy.
Facts & Figures
From Heng 2013.
Original/Primary ReferenceHeng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C,McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. JCO Dec 1, 2009:5794-5799; published online on October 13, 2009.
About the Creator
Daniel Heng, MD, is a clinical associate professor of medicine at the University of Calgary and practicing medical oncologist at the Tom Baker Cancer Center in Calgary. Dr. Heng is currently the chair of the Genitourinary Tumor Group in Calgary and is the chair of the International Metastatic Renal Cell Cancer Database Consortium. His research focuses on outcomes, prognostic factors, and clinical trials metastatic renal cell carcinoma and other genitourinary malignancies.
To view Dr. Daniel Heng's publications, visit PubMed